Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study

BACKGROUND: Two recombinant enzymes (agalsidase alfa 0.2 mg/kg/every other week and agalsidase beta 1.0 mg/kg/every other week) have been registered for the treatment of Fabry disease (FD), at equal high costs. An independent international initiative compared clinical and biochemical outcomes of the...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Med Genet
Hlavní autoři: Arends, Maarten, Biegstraaten, Marieke, Wanner, Christoph, Sirrs, Sandra, Mehta, Atul, Elliott, Perry M, Oder, Daniel, Watkinson, Oliver T, Bichet, Daniel G, Khan, Aneal, Iwanochko, Mark, Vaz, Frédéric M, van Kuilenburg, André B P, West, Michael L, Hughes, Derralynn A, Hollak, Carla E M
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2018
Témata:
Therapeutics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5931248/
https://ncbi.nlm.nih.gov/pubmed/29437868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jmedgenet-2017-104863
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky